Improved manufacturing process of bosentan monohydrate.

Wojciech Łuniewski ,  Katarzyna Sidoryk ,  Maria Puchalska ,  Marta Łaszcz ,  Wioleta Maruszak ,  Marta Jatczak 

Pharmaceutical Research Institute (IF), Rydygiera 8, Warszawa 01-793, Poland

Abstract

Bosentan is first oral dual endothelin A and B receptor (ETA/ETB) antagonist. The drug is indicated for the treatment of pulmonary arterial hypertension (PAH). In patients with systemic sclerosis and ongoing digital ulcer disease it is used for the reduction of new digital ulcers.

The synthesis of bosentan was carried out according to the scheme shown below, described in the patent EP 0526708. The main problem in this synthesis was obtaining pharmaceutical grade bosentan, due to the presence of three impurities in the final product. All these impurities were very difficult to remove. Improved methods of bosentan synthesis or purification of bosentan are described in many patent applications however, the problem of the obtaining pharmaceutical grade bosentan with a good yield had to be reconsidered.

bo_mknol.gif

We have investigated all steps of this process, and we have developed the best conditions in the last key step of the synthesis. The synthesis of bosentan was optimized, all chemical and degradation impurities were isolated or synthesized and characterized by NMR, MS and HPLC techniques. Moreover, the efficient method of bosentan purification was developed. We obtained bosentan with a proper polymorphic form and particle size favorable for a pharmaceutical formulation. Furthermore, X-ray single-crystal investigation of bosentan unambiguously proved its structure.

These allowed us to develop the large scale efficient synthesis of pharmaceutical grade bosentan containing < 0,1 % of known impurities and <  0,5 % of total impurities.

 

Related papers
  1. The comparison of the stability indicating  two HPLC methods and their application for the determination of bosentan in coated tablets 
  2. Influence of the side chain on the cytotoxicity of betulin derivatives
  3. Synthesis of new 5H-indolo[2,3-b]quinoline derivatives with a high selective cytotoxic activity
  4. Application of the new data processing method for photodiode array detector in the analysis of drug substances
  5. Development and validation of the GC method for quantitative determination of semi-volatile solvents in pharmaceutical substance Bosentan
  6. Characterization of dutasteride polymorphic forms
  7. Evaluation of potential genotoxic impurities in prasugrel intermediate by HPLC chromatography
  8. Validation of HPLC methods for analyzing the chemical purity of cilostazol
  9. Simultaneous CE determination of counterion and possible impurity from synthetic route in pharmaceutical substance prasugrel hydrochloride.
  10. Preparation and physicochemical properties of crystalline forms and amorphous pemetrexed disodium
  11. An application of accelerator mass spectrometry (AMS) in pediatric clinical studies. Paracetamol, midazolam and spironolactone radiosynthesis and certification.
  12. Assessment of selected synthesis of bosentan towards elimination of known impurities.
  13. New cyclic dermorphin analogues containing a carbonyl bridge
  14. Investigation of unknown impurities in cyclic dermorphin analogue by HPLC-MS
  15. Development and validation of the HPLC-UV method for impurities determination in duloxetine hydrochloride
  16. 5H-indolo-[2,3-b]quinolines loaded polymeric micelles
  17. Development and validation of HPLC method. Review of selected cases.
  18. Physicochemical characterization of sunitinib and its impurities
  19. Distinguishing between polymorphic forms of linezolid by solid-phase electronic and vibrational circular dichroism
  20. Preparation of protoaescigenin from escin.
  21. Synthesis and biological evaluation of new amino acid and dipeptide derivatives of neocryptolepine as anticancer agents. 
  22. Opimisation of preparation of TZ-6
  23. HPLC method as an analitycal control of synthesis and determination of TZ-S
  24. The synthesis of ezetimibe with high stereochemical purity
  25. Investigation of unknown impurity of TD-S by HPLC-MS
  26. Validation of a HPLC method for LI-S analysis
  27. HPLC Methods for Stress Testing of ZL-S Drug Substances
  28. Structural characterization of PX-S
  29. New amino acid and peptide derivatives of 5H-indolo[2,3-b]quinoline and their biological activity.
  30. Quantification of active substance in drug by Rietveld analysis
  31. The evaluation of tolterodine tartrate synthesis based on patent EP 0 325 574 B1.
  32. Disubstituted indolo[2,3-b]quinoline derivatives - the cytotoxic activity in vitro against various human tumor cell lines.
  33. Mono substituted 5H- and 6H-indolo[2,3-b]quinoline derivatives and their ability to overcome the barrier of drug resistance.
  34. Synthesis of selected 14C radiolabelled compounds in recent investigations of new analytical method applied in accelerated drug development (EUMAPP).
  35. HPLC as a method for analytical control of synthesis and determination of tolterodine (TD-S)
  36. New rosiglitazone salts
  37. High-yielded method of synthesis of voriconazole.
  38. Development of HPLC and GC methods for analysis of Zolmitriptan of pharmaceutical purity
  39. Optimization of AR-3 synthesis
  40. New amino acid derivatives of 6H-indolo[2,3-b]quinolines
  41. ROPINIROL - GENERIC DRUG FOR PARKINSON'S DISEASE
  42. QUINONES AND HYDROQUINONES SEPARATION AND DETERMINATION BY HPLC CHROMATOGRAPHY
  43. CHARACTERIZATION OF ARIPIPRAZOLE SOLVATE WITH ETHANOL AND POLYMORPHIC FORMS PRODUCED DURING ITS HEATING
  44. THE VALIDATION OF ANALYTICAL METHODS OF A PHARMACEUTICAL ACTIVE SUBSTANCE PRODUCED IN SMALL SCALE PLANT (SSP). THE EXAMPLE OF PIOGLITAZONE HYDROCHLORIDE.
  45. MONO SUBSTITUTED 5H-INDOLO[2,3-B]- QUINOLINE DERIVATIVES AND THEIR ABILITY TO OVERCOME THE BARRIER OF DRUG RESISTANCE.
  46. DISUBSTITUTED INDOLO[2,3-b]QUINOLINE DERIVATIVES. THE CYTOTOXIC ACTIVITY IN VITRO AGAINST VARIOUS HUMAN TUMOR CELL LINE.
  47. NEW IMPROVED METHOD OF POLYMORPHIC α FORM OF IMATINIB MESYLATE (GLEEVEC®) SYNTHESIS.
  48. THE COMPARISON OF TWO VALIDATED HPLC METHODS FOR THE DETERMINATION OF (+)-CLOPIDOGREL HYDROGENSULFATE PURITY WITH THE USP METHOD.

Presentation: Poster at IX Multidyscyplinarna Konferencja Nauki o Leku, by Wojciech Łuniewski
See On-line Journal of IX Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2014-03-14 09:05
Revised:   2014-04-29 11:42